Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | PRKDC | P78527 | 6/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17189525 | 0.97 | ALOX5 (0.46) | ALOX5PRKDCGGPS1BRDTPTGES2 | |
| SCHEMBL26510518 | 0.92 | ALOX5 (0.46) | ALOX5PRKDCGGPS1BRDTPTGES2 | |
| SCHEMBL23737652 | 0.91 | ALOX5 (0.34) | ALOX5PRKDCBRDT | |
| SCHEMBL26510516 | 0.90 | ALOX5 (0.46) | ALOX5PRKDCGGPS1BRDTPTGES2 | |
| SCHEMBL17248447 | 0.89 | PLA2G2A (0.36) | PRKDCPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL17248388 | 0.88 | ALOX5 (0.48) | ALOX5PRKDCGGPS1PTGES2PRMT5 | |
| SCHEMBL26507352 | 0.87 | PRKDC (0.42) | ALOX5PRKDCGGPS1PTGES2 | |
| SCHEMBL15888826 | 0.87 | PRKDC (0.35) | ALOX5PRKDCBRDT | |
| SCHEMBL17189522 | 0.87 | SMN1; SMN2 (0.34) | PRKDCBRDTPLA2G2APLA2G4APLA2G10 | |
| SCHEMBL22107004 | 0.85 | BRDT (0.34) | ALOX5PRKDCGGPS1BRDTPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10361378-B2 | Organic electroluminescent device | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2019-07-23 | — | — | US | disclosed |
| US-20150325796-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150325796-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10361378-B2 | Organic electroluminescent device | ELF3, DDT, LEF1 | ALOX5 1717/4885PRKDC 1748/4885GGPS1 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.